PTK2 and cancer: Moreover, we unveiled a previously unknown Abl kinase-dependent retrograde signaling pathway mediated by transmembrane Sema6C, upregulating FAK, ERK and YAP activity in cancer cells, and conferring refractoriness to cell cycle inhibitory mechanisms.